Early Provider Perspectives on Itvisma’s Approval and Adoption Pathway Tracking Study

A New Chapter in SMA Care

Itvisma, newly approved for SMA (Spinal Muscular Atrophy) patients aged two and older, introduces an intrathecal one-time gene therapy that expands treatment options beyond infancy, prompting an exploration of early provider reactions to its approval.

What you’ll learn:

This tracking study highlights

How neurologists and neuromuscular specialists perceive Itvisma following its approval, including awareness, interest, and anticipated timing to prescribe.
The key clinical, operational, and access-related factors shaping real-world prescribing decisions.
Strong early enthusiasm paired with meaningful barriers around safety, insurance coverage, cost, and infrastructure.
Reveals the clinical, access, and support factors that will ultimately determine adoption in SMA (Spinal Muscular Atrophy) care

Complete this form to Download this Tracking Study on How Providers View Itvisma to gain a deeper insight into how early provider enthusiasm for Itvisma is balanced by real-world concerns.

We’re introducing a new era of healthcare market research — one that’s faster, smarter, and more connected.

Download our ebook, “The Evolution of Market Research in Healthcare,” to discover the trends redefining the field and how Konovo is helping companies turn insight into action.